<DOC>
	<DOCNO>NCT03088527</DOCNO>
	<brief_summary>The primary purpose study evaluate clinical safety profile , tolerability , pharmacokinetic ( PK ) characteristic RAD140 hormone receptor positive breast cancer .</brief_summary>
	<brief_title>A Phase 1 , First-in-Human , Multi-Part Study RAD140 Postmenopausal Women With Hormone Receptor Positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Key Progressive metastatic locally advanced metastatic breast cancer . Clinically confirm postmenopausal . Eastern Cooperative Oncology Group ( ECOG ) score 0 1 screening . Key HER2 positive patient local laboratory test . Triple negative breast cancer . Any chemotherapy within 28 day prior first dose study drug . Any nonchemotherapy anticancer drug le 5 halflives ( 30 day biologics ) less 14 day small molecule therapeutic , halflife know . Tamoxifen aromatase inhibitor within 14 day prior first dose study drug . Fulvestrant within 30 day prior first dose study drug . Any investigational drug therapy within 5 halflives previous investigational study drug 30 day , whichever short . Radiation therapy breast cancer within 2 week dose plan radiation therapy participation study . Known history human immunodeficiency virus infection ( HIV ) hepatitis C active hepatitis B infection , unless patient diagnose &gt; 10 year prior enrollment evidence active liver disease . Currently take testosterone , methyltestosterone , oxandrolone ( Oxandrin ) , oxymetholone , danazol , fluoxymesterone ( Halotestin ) , testosteronelike agent . Untreated uncontrolled brain metastasis . Diagnosed treated cancer within previous 2 year , breast cancer nonmelanoma carcinoma skin . Pregnant nursing female .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>